晚期慢性肾脏病过渡至透析患者透析前血清碱性磷酸酶对终末期肾病后死亡率的预后意义
本研究纳入17732例于2007年10月至2011年9月间过渡至透析的美国退伍军人,分析透析前6个月血清碱性磷酸酶(ALP)平均水平与透析启动后全因、心血管及感染相关死亡率的关联。中位随访2.0年期间发生9196例全因死亡,ALP最高四分位组(≥111.1 U/L)较最低四分位组(<66.0 U/L)的全因死亡风险比为1.42(95%CI 1.34-1.51)。作者认为透析前ALP升高与透析后死亡风险独立相关,并建议进一步研究降低ALP能否减少新入透析患者死亡。
要点
- 透析前6个月平均血清ALP最高四分位组(≥111.1 U/L)全因死亡风险比为1.42(95%CI 1.34-1.51)。
- 心血管死亡及感染相关死亡的校正风险比分别为1.43(95%CI 1.09-1.88)和1.39(95%CI 1.09-1.78)。
- 作者建议进一步研究降低透析前ALP水平的干预能否减少新入透析患者死亡。
核心结论
- 透析前血清ALP水平升高与透析启动后全因、心血管及感染相关死亡风险独立相关。
- 作者建议进一步研究降低透析前ALP水平的干预能否减少新入透析患者死亡。
研究设计与样本
- 回顾性队列研究,纳入17732例于2007年10月至2011年9月间过渡至透析的美国退伍军人。
- 暴露为透析前过渡期(prelude period)最后6个月血清ALP平均水平。
- 采用Cox回归分析全因死亡,采用竞争风险回归分析病因特异性死亡,校正人口学、合并症、药物、估算肾小球滤过率、血清白蛋白及透析启动时血管通路类型。
主要发现
- 透析启动后中位随访2.0年(四分位距1.1-3.2年),共发生9196例全因死亡。
- ALP水平升高与全因、心血管及感染相关死亡率呈递增关联。
- 与最低四分位组(<66.0 U/L)相比,最高四分位组(≥111.1 U/L)的全因死亡风险比为1.42(95%CI 1.34-1.51)。
- 最高四分位组(≥111.1 U/L)较最低四分位组(<66.0 U/L)的心血管死亡风险比为1.43(95%CI 1.09-1.88)。
- 最高四分位组(≥111.1 U/L)较最低四分位组(<66.0 U/L)的感染相关死亡风险比为1.39(95%CI 1.09-1.78)。
关键数值与推荐
- ALP最低四分位组为<66.0 U/L,最高四分位组为≥111.1 U/L。
- 最高四分位组(≥111.1 U/L)较最低四分位组(<66.0 U/L)全因死亡风险比1.42(95%CI 1.34-1.51)。
- 最高四分位组(≥111.1 U/L)较最低四分位组(<66.0 U/L)心血管死亡风险比1.43(95%CI 1.09-1.88)。
- 最高四分位组(≥111.1 U/L)较最低四分位组(<66.0 U/L)感染相关死亡风险比1.39(95%CI 1.09-1.78)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出需要进一步研究以确定降低透析前ALP水平的干预能否减少新入透析患者的死亡率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Higher serum alkaline phosphatase (ALP) levels have been associated with excess mortality in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) and end-stage renal disease (ESRD). However, little is known about the impact of late-stage NDD-CKD ALP levels on outcomes after dialysis initiation. METHODS: Among 17 732 US veterans who transitioned to dialysis between October 2007 and September 2011, we examined the association of serum ALP levels averaged over the last 6 months of the pre-ESRD transition period ('prelude period') with all-cause, cardiovascular and infection-related mortality following dialysis initiation, using Cox (for all-cause mortality) and competing risk (for cause-specific mortality) regressions adjusted for demographics, comorbidities, medications, estimated glomerular filtration rate and serum albumin levels over the 6-month prelude period, and vascular access type at dialysis initiation. RESULTS: During a median follow-up of 2.0 (interquartile range, 1.1-3.2) years following dialysis initiation, a total of 9196 all-cause deaths occurred. Higher ALP levels were incrementally associated with higher all-cause, cardiovascular and infection-related mortality. Compared with patients in the lowest ALP quartile (<66.0 U/L), those in the highest quartile (≥111.1 U/L) had multivariable-adjusted hazard/subhazard ratios (95% confidence interval) of 1.42 (1.34-1.51), 1.43 (1.09-1.88) and 1.39 (1.09-1.78) for all-cause, cardiovascular and infection-related mortality, respectively. The associations remained consistent in various subgroups and after further adjustment for liver enzymes, serum phosphorus and intact parathyroid hormone levels. CONCLUSIONS: Higher pre-ESRD serum ALP levels are independently associated with higher post-ESRD mortality risk. Further studies are warranted to determine if interventions that lower pre-ESRD ALP levels reduce mortality in incident dialysis patients.
引用
- Sumida K, Molnar MZ, Potukuchi PK, et al. Prognostic significance of pre-end-stage renal disease serum alkaline phosphatase for post-end-stage renal disease mortality in late-stage chronic kidney disease patients transitioning to dialysis. Nephrol Dial Transplant. 2018. PMID: 28064159. doi:10.1093/ndt/gfw412
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。